An observational study in Subarachnoid Aneurysm Hemorrhage, Microsurgery and Cognitive Impairment, sponsored by University of Campinas, Brazil. Not yet recruiting at 1 site in Brazil. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by University of Campinas, Brazil · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Cognitive Dysfunction with a site in Brazil — 10 open to participants now, 14 under way, 6 of them phase 3. Cognitive Dysfunction · Brazil.
Among the 40 studies in Cognitive Dysfunction with a site in Brazil, this one is one of 5 that started in 2026, is one of 6 observational ones, reaches primary completion later than 10 of the 13 other live ones, and was the 39th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →10 of the 40 studies in Cognitive Dysfunction with a site in Brazil are open now. Recruiting first, the newest first:
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Brazil, Australia, Austria and 14 more countries
Ages 18+
Getúlio Vargas University Hospital · Sites in Brazil
Ages 65+ · Healthy volunteers
Bristol-Myers Squibb · Sites in Brazil, United States, Argentina and 14 more countries
Ages 60–85
Bristol-Myers Squibb · Sites in Brazil, United States, Argentina and 16 more countries
Ages 60–85
Hoffmann-La Roche · Sites in Brazil, United States, Argentina and 12 more countries
Ages 50–90
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 9 · Phase 4 2
First in 2007; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is close to the median of 150 across 1,000 observational studies indexed under Cognitive Dysfunction.
Median enrollment 70 across the 34 interventional studies, 155 across the 6 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 40 have an industry lead sponsor. The 10 most frequent:
University of Campinas, Brazil is the lead sponsor of 169 studies on the registry; 13 are open to participants now.
University of Campinas, Brazil has 2 studies filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
4 of the studies in Cognitive Dysfunction with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03263247São Paulo State UniversityCognitive Training in Patients With MCI Using fMRI | 2026-12-31 |
| NCT06733714Universidade Federal do Rio de JaneiroAssociation of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation in Older Adults | 2027-03-01 |
| NCT07391436Getúlio Vargas University HospitalUse of Wearables for Identifying Factors Associated With Mild Cognitive Impairment and Early-Stage Alzheimer's Disease | 2027-07 |
| NCT07731529Federal University of Rio Grande do SulVivifrail Exercise Program in Nonagenarians: Effects on Function, Muscle, and Cognition | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 40 studies in Cognitive Dysfunction with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigates the clinical and structural predictors of long-term cognitive impairment in patients who underwent microsurgical clipping for aneurysmal subarachnoid hemorrhage. Using a retrospective cohort with prospective neuropsychological and MRI assessments, it aims to identify factors associated with late cognitive deficits and improve prognostic stratification, rehabilitation planning, and long-term patient care.
Aneurysmal subarachnoid hemorrhage (aSAH) is associated with substantial morbidity, even among patients who remain functionally independent after treatment. Late cognitive deficits, particularly involving memory, attention, and executive function, are common in patients undergoing microsurgical clipping of ruptured cerebral aneurysms; however, the underlying mechanisms remain poorly understood. This study aims to identify clinical, acute radiological, and late structural predictors associated with cognitive impairment in these patients.
Participants will undergo a standardized late postoperative brain magnetic resonance imaging (MRI) evaluation (>1 year after treatment). Structural imaging variables to be analyzed as potential predictors of cognitive impairment include the presence or absence of hippocampal atrophy, frontal lobe atrophy, posterior cerebellar atrophy, pituitary gland atrophy, and deep gray nuclei atrophy, as well as quantitative measurements of white matter hyperintensity volume on FLAIR MRI, residual infarct volume, and cerebral perfusion. These imaging variables will be evaluated in combination with clinical and acute radiological characteristics to identify independent predictors of late cognitive impairment.
Adult patients who underwent microsurgical clipping of ruptured cerebral aneurysms following aneurysmal subarachnoid hemorrhage (aSAH), with symptom onset occurring in or after 2020, and who are currently under outpatient follow-up at HC-UNICAMP, will be eligible for inclusion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients submited to microsurgical clipping \<24h after aneurysmal subarachnoid hemorrhage
Patients submited to microsurgical clipping between 24h and 72h after aneurysmal subarachnoid hemorrhage
Patients submited to microsurgical clipping \>72h after aneurysmal subarachnoid hemorrhage
Montreal Cognitive Assessment (MoCA) score
The MoCA is a global cognitive screening test with scores ranging from 0 to 30, where higher scores indicate better cognitive function. Cognitive impairment is defined as a MoCA score \<25, adjusted for educational level. A secondary analysis will also classify participants with MoCA \<23, adjusted for educational level, representing unfavorable functional outcome.
Time frame: Through study completion, an average of 3 years
EuroQol 5-Dimension 5-Level (EQ-5D-5L)
The EQ-5D-5L descriptive system generates a health utility index score ranging from less than 0 (health states considered worse than death) to 1.0 (full health), depending on the country-specific value set. Higher scores indicate better health-related quality of life.
Time frame: Through study completion, an average of 3 years
Hospital Anxiety and Depression Scale (HADS)
proportion of patients with anxiety or depression. The HADS consists of two subscales: HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D), each ranging from 0 to 21, with higher scores indicating greater symptom severity. The outcome is defined as the proportion of participants with a score ≥8 on either the HADS-A (anxiety) or HADS-D (depression) subscale, consistent with clinically significant symptoms.
Time frame: Through study completion, an average of 3 years
Modified Rankin Scale (mRS)
proportion of patients with favorable functional outcome. The Modified Rankin Scale ranges from 0 to 6, where 0 indicates no symptoms, 5 indicates severe disability requiring constant care, and 6 indicates death. Higher scores indicate worse functional outcome. The outcome is defined as the proportion of participants with a favorable functional outcome (mRS 0-2) versus an unfavorable functional outcome (mRS 3-6).
Time frame: Through study completion, an average of 3 years
Return to work
proportion of patients returning to work. This outcome is defined as the proportion of participants who returned to paid employment after aneurysmal subarachnoid hemorrhage and microsurgical clipping (yes/no). Among participants who returned to work, the proportion requiring workplace adaptations or modifications (yes/no) will also be assessed.
Time frame: Through study completion, an average of 3 years
In-hospital complications
Proportion of participants experiencing in-hospital complications. Each complication will be recorded as a binary outcome (yes/no) during the index hospitalization for aneurysmal subarachnoid hemorrhage. Complications include aneurysm rebleeding, hydrocephalus, need for surgical revision, infection, and delayed cerebral ischemia.
Time frame: Through study completion, an average of 3 years
Plan to share: Yes — Yes. De-identified individual participant data will be made available upon reasonable request to the corresponding author, following publication of the primary results, subject to approval of a data access agreement and institutional/ethical requirements.
Supporting information: Study protocol, Informed consent form
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Jul 2029, 35 months later.
Of 506 non-industry observational studies under Cognitive Dysfunction, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's planned 35 months is below that.
Counting every sponsor, half of 545 studies reached it within 48 months; a quarter within 21 and three quarters within 118.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Campinas, Brazil →